Scarica l'app Stockscreener
32.40
5.98%
-2.06
Dopo l'orario di chiusura:
32.43
0.03
+0.09%
Precedente Chiudi:
$34.46
Aprire:
$34.06
Volume 24 ore:
64,479
Relative Volume:
1.31
Capitalizzazione di mercato:
$688.30M
Reddito:
$54,000
Utile/perdita netta:
$-210.26M
Rapporto P/E:
-41.01
EPS:
-0.79
Flusso di cassa netto:
$-159.01M
1 W Prestazione:
+14.25%
1M Prestazione:
+91.38%
6M Prestazione:
+232.65%
1 anno Prestazione:
+140.43%
Intervallo 1D:
$32.38
$34.66
Intervallo di 1 settimana:
$27.00
$35.16
Portata 52W:
$7.65
$35.16
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Nome
Lyell Immunopharma Inc
Settore
Industria
Telefono
650 695-0677
Indirizzo
201 HASKINS WAY, SOUTH SAN FRANCISCO
Confronta LYEL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
32.40 | 732.07M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-10-30 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-06-27 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-11-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-17 | Iniziato | H.C. Wainwright | Buy |
| 2021-07-12 | Iniziato | BofA Securities | Buy |
| 2021-07-12 | Iniziato | Goldman | Buy |
| 2021-07-12 | Iniziato | JP Morgan | Overweight |
| 2021-07-12 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Lyell Immunopharma Inc Borsa (LYEL) Ultime notizie
HSG Holding Ltd Cuts Position in Lyell Immunopharma, Inc. $LYEL - MarketBeat
1,820,634 Shares in Lyell Immunopharma, Inc. $LYEL Bought by ARCH Venture Management LLC - Defense World
Lyell ImmunoPharma announces new data from trial of rondecabtagene autoleucel - MSN
Lyell Immunopharma (NASDAQ:LYEL) Sets New 12-Month HighShould You Buy? - MarketBeat
Aug Technicals: Why Lyell Immunopharma Inc stock could outperform in 2025Weekly Gains Summary & Smart Swing Trading Alerts - moha.gov.vn
Lyell Immunopharma (NASDAQ:LYEL) Trading Up 11.4%Should You Buy? - MarketBeat
What analysts say about Lyell Immunopharma Inc stockConsumer Goods Stocks & High Return Capital Growth - earlytimes.in
100,000 Shares in Lyell Immunopharma, Inc. $LYEL Bought by RBF Capital LLC - MarketBeat
Lyell Immunopharma Shares Rise After HC Wainwright Upgrade - marketscreener.com
H.C. Wainwright upgrades Lyell to 'buy' on cell therapy progression - TradingView — Track All Markets
This Eaton Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors - GlobeNewswire Inc.
LYEL Analyst Rating Upgrade: HC Wainwright & Co. Sets New Price Target | LYEL Stock News - GuruFocus
HC Wainwright & Co. Upgrades Lyell Immunopharma (LYEL) - Nasdaq
Lyell Immunopharma climbs after reporting strong CAR T-cell therapy results - MSN
Lyell Immunopharma stock rises on strong cancer therapy trial data By Investing.com - Investing.com Nigeria
Lyell Immunopharma stock rises on strong cancer therapy trial data - Investing.com
Lyell Immunopharma Presents Promising CAR T-Cell Data - TipRanks
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition - GlobeNewswire
Lyell Immunopharma (Nasdaq: LYEL) posts 76% complete responses with ronde-cel in LBCL - Stock Titan
Lyell Immunopharma (NASDAQ:LYEL) Sets New 12-Month High – Here’s What Happened - Defense World
Lyell Immunopharma Modernizes Bylaws for Shareholder Engagement - TipRanks
Lyell Immunopharma (NASDAQ:LYEL) Stock Price Up 11.6%Should You Buy? - MarketBeat
Will Lyell Immunopharma Inc. stock sustain high P E ratiosTrade Signal Summary & Growth Oriented Trading Recommendations - Newser
Decheng Capital LLC Sells 11,313,875 Shares of Lyell Immunopharma, Inc. $LYEL - MarketBeat
ASH 2025 Roundup: Companies With Key Data Presentations - RTTNews
What drives Lyell Immunopharma Inc stock priceHigh Beta Stocks & Free High Yield Growth Strategies - earlytimes.in
Lyell Immunopharma (NASDAQ:LYEL) Hits New 52-Week HighHere's What Happened - MarketBeat
Lyell Immunopharma Secures Global Rights for LYL273 - MSN
Published on: 2025-11-26 22:33:12 - BỘ NỘI VỤ
Foresite Capital Management V LLC Trims Stock Position in Lyell Immunopharma, Inc. $LYEL - MarketBeat
Lyell Immunopharma (LYEL) Sees Price Target Doubling by HC Wainw - GuruFocus
ETFs Investing in Lyell Immunopharma, Inc. Stocks - TradingView
Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) one-year returns climbed after last week's 13% gain, institutional investors must be happy - simplywall.st
Is Lyell Immunopharma Inc. stock trading at a premium valuationJuly 2025 Trends & AI Powered Trade Plan Recommendations - newser.com
How Lyell Immunopharma Inc. stock performs in rate cut cyclesJuly 2025 Momentum & Technical Pattern Based Signals - newser.com
Will Lyell Immunopharma Inc. stock pay special dividendsJuly 2025 Institutional & Accurate Technical Buy Alerts - newser.com
Real time social sentiment graph for Lyell Immunopharma Inc.Weekly Profit Report & Reliable Volume Spike Trade Alerts - newser.com
Will Lyell Immunopharma Inc. benefit from macro trendsQuarterly Portfolio Review & Fast Exit and Entry Trade Guides - newser.com
How Lyell Immunopharma Inc. stock performs in weak economyTrade Exit Summary & Real-Time Stock Entry Alerts - newser.com
Is it too late to sell Lyell Immunopharma Inc.Weekly Investment Recap & Daily Stock Momentum Reports - newser.com
Is Lyell Immunopharma Inc. stock attractive for retirement portfoliosLayoff News & Safe Entry Point Alerts - newser.com
Lyell Immunopharma Inc Azioni (LYEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):